# Advisor Review - GPT-5.2

**Role:** Academic advisor checking for fatal errors
**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Timestamp:** 2026-01-30T22:41:01.514521
**Response ID:** resp_020ee07552773f1b00697d2369b74481968170359e9db41cae
**Tokens:** 28186 in / 16702 out
**Response SHA256:** b393044876c57cb8

---

## 1) DATA–DESIGN ALIGNMENT (CRITICAL)

**a) Treatment timing vs. data coverage:**  
- Outcome data: **2015–2019, 2021–2022** (explicitly excludes 2020), so **max outcome year = 2022**.  
- Treatment cohorts (Table 7) run through **2021**, so **max treatment year = 2021 ≤ 2022**.  
✅ No timing impossibility.

**b) Post-treatment observations for treated cohorts:**  
- Latest cohort **2021 (NV, VA)** has post-treatment outcomes in **2021 and 2022**.  
- Cohort **2020 (NM)** has no outcome in 2020 (missing ACS), but does have post outcomes in **2021–2022**, so the cohort can still contribute to post-period ATT (though not to an “impact in adoption year” cell).  
✅ No cohort is “treated but with zero post-treatment outcome years” in the outcome panel.

**c) Treatment definition consistency across tables/text:**  
- Treatment is consistently defined as first year **effective MW ≥ federal + $1.00** (Abstract; Sections 4.2, 5.1; Table 7; Figure 1).  
- Counts are consistent: **31 treated + 20 never-treated = 51 jurisdictions** (Table 7 totals match the text).  
✅ No internal treatment-definition mismatch.

## 2) REGRESSION SANITY (CRITICAL)

Scanned all reported tables with estimates:

- **Table 2:** Coefficients (0.000, −0.540, −0.880) and SEs (0.381, 0.446, 0.622) are plausible for percentage-point outcomes. R² values in [0,1]. No impossible values.  
- **Table 3:** Event-study SEs are finite; the largest (SE = 3.441 at e = −4) is large but not mechanically impossible and does not violate your stated fatal thresholds (no SE in the thousands; not >100× |coef|).  
- **Table 4:** Sun–Abraham coefficients/SEs are in reasonable ranges; no NA/Inf/NaN; R² in [0,1].  
- **Tables 5, 6, 9:** Reported ATTs/SEs are finite and plausible.  
✅ No “broken regression output” indicators (no NA/NaN/Inf, no negative SEs, no R² outside [0,1], no absurd coefficient magnitudes).

## 3) COMPLETENESS (CRITICAL)

- No placeholders (“TBD”, “TODO”, “XXX”, NA cells) found in the presented tables/figures.  
- Main regression tables (Tables 2, 3, 4) report **SEs** and **N** (or N in notes).  
- Robustness checks discussed in text are actually reported in Table 5 / Table 6 (with estimates and SEs).  
- Figures referenced (Figures 1–6) appear and match their numbering/descriptions in the draft excerpt.  
✅ No fatal incompleteness.

## 4) INTERNAL CONSISTENCY (CRITICAL)

- Key headline numbers match across text and tables:  
  - Overall CS-DiD ATT **−0.540 (SE 0.446)** appears consistently (Abstract; Table 2 col 2; Table 3 “Overall ATT”; Table 5 baseline; Table 9 Panel A).  
  - Reported 95% CI **[−1.414, 0.334]** matches −0.540 ± 1.96×0.446 (Table 3 and Introduction).  
- Panel size is consistent: **51 × 7 = 357** (Table 1; Section 4.4), with Sun–Abraham at **356** due to a stated drop.  
✅ No fatal numeric contradictions located.

ADVISOR VERDICT: PASS